GlassScriptPhysician profile
Richard M Fruehling
NPI 1851347611
$895.46
in general payments reported to CMS, 2019-2025
20 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.05 · 2020: $25.44 · 2022: $52.63 · 2023: $185 · 2024: $242 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $166.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $103.32 | 2022-2025 | |
| Abbott Laboratories | $97.13 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $63.45 | 2023-2025 | Mounjaro, Emgality, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $58.07 | 2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $41.78 | 2023-2024 | Airsupra, Breztri |
| Exact Sciences Corporation | $41.31 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $39.82 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.01 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $36.34 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.66 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $30.02 | 2023 | Arexvy, Shingrix |
| Optinose US, INC. | $24.39 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.46 | 2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $22.91 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.92 | 2024 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $19.41 | 2025 | Rezdiffra |
| Ardelyx, INC. | $16.63 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $13.09 | 2023 | |
| Phathom Pharmaceuticals, INC. | $6.09 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Fruehling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.